Interaction Guide · Research summary

Can I take Willow Bark with Etodolac?

Review Willow Bark with Etodolac: possible adverse effects, preparation details, evidence limits, and sources.

Prepared by Dr. Edward M.Kim, PharmD · Clinical Director, SupplementSafety editorial team

Research summary published · Prepared · Editorial update

The short answer

Ask your prescriber before adding willow bark to etodolac. Medicinal willow guidance advises medical review with NSAIDs, but the exact added bleeding risk and a protective spacing interval are unknown.

What this answer covers

Oral willow bark products with oral immediate-release etodolac capsules or tablets. Medicinal Salix bark guidance has defined preparation scope; exact species and salicin content must be checked.

Supplement or preparation
Willow Bark
Medication ingredient
etodolac

The monograph calls for medical advice

The final European medicinal willow bark monograph advises against combining its covered preparations with salicylates or other NSAIDs without medical advice. oral immediate-release etodolac capsules or tablets is an NSAID, so this is a relevant reason for review, while the exact combination’s bleeding risk remains unmeasured.

The species and product still matter

Willow bark products vary in Salix species, extract and salicin content. Show the pharmacist the full label rather than assuming all willow products are interchangeable or equivalent to aspirin.

Consider your stomach and bleeding history

The willow monograph contraindicates use with active peptic ulcer and NSAID hypersensitivity. The prescription medicine also carries GI warnings. Tell your clinician about past ulcers, bleeding, aspirin reactions and other pain relievers before adding a botanical product for pain.

Do not rely on a few hours of separation

No established spacing interval has been shown to prevent the potential overlapping effects. Ask for a pain-management plan that accounts for the exact preparation and your history. Seek urgent care for vomiting blood or black, tarry stools, and report persistent stomach discomfort promptly.

Evidence and practical considerations

Side effects & toxicity

An exact increase in bleeding or GI injury from willow bark with etodolac has not been measured.

Exact scope
Oral willow bark products with oral immediate-release etodolac capsules or tablets. Medicinal Salix bark guidance has defined preparation scope; exact species and salicin content must be checked. with Exact etodolac IN 24605. Racemic immediate-release capsules 200/300 mg and tablets 400/500 mg; extended-release or isolated enantiomer exposures are not assumed equivalent.
Medication form and route
Oral

What remains uncertain

  • Regulatory NSAID co-use warning is precautionary. Unspecified willow bark products may differ from the defined medicinal preparations.

Factors that may matter: Exact preparation and dose; Fasting versus fed dosing; Bleeding and ulcer history; Other medicines.

Research conclusion: insufficient evidence · Evidence assessment: low

Read the supporting source summaries

Source 1: Current prescribing information

dailymed.nlm.nih.gov · Source check Sep 10, 2026

Population: Prescription oral oral immediate-release etodolac capsules or tablets users; short human pharmacology studies where described.

GI bleeding, renal and hematological warnings; assess anemia symptoms rather than assuming nutritional deficiency.

How this applies: Exact current product label. Exact etodolac IN 24605. Racemic immediate-release capsules 200/300 mg and tablets 400/500 mg; extended-release or isolated enantiomer exposures are not assumed equivalent.

Exact oral product label; no measured botanical co-use incidence. Ingredient, route, preparation and comparator differences must be retained.

Source 2: Final regulatory herbal monograph

ema.europa.eu · Source check Sep 10, 2026

Population: Users of defined Salix bark preparations.

Advises against concomitant salicylates or other NSAIDs without medical advice; active ulcer and NSAID hypersensitivity are contraindications.

How this applies: Precaution for medicinal willow products; exact S. alba applicability remains limited by botanical identification.

No exact pair bleeding estimate. Defined medicinal species/preparations cannot authenticate unspecified products. Salix alba is not specifically named among the principal listed species.

Source 3: Medication terminology

rxnav.nlm.nih.gov · Source check Sep 10, 2026

Population: Terminology.

etodolac is IN.

How this applies: Exact identity.

Not clinical evidence.

Research assessment: · Open full citations ↗

Side effects & toxicity

Medicinal willow bark should not be added to an NSAID without medical advice.

Exact scope
Oral willow bark products with oral immediate-release etodolac capsules or tablets. Medicinal Salix bark guidance has defined preparation scope; exact species and salicin content must be checked. with Exact etodolac IN 24605. Racemic immediate-release capsules 200/300 mg and tablets 400/500 mg; extended-release or isolated enantiomer exposures are not assumed equivalent.
Medication form and route
Oral

What remains uncertain

  • Supported for defined medicinal willow products; not a measured exact-species combination risk, universal salicin dose or validated timing solution.

Factors that may matter: Exact preparation and dose; Fasting versus fed dosing; Bleeding and ulcer history; Other medicines.

Research conclusion: supported with conditions · Evidence assessment: moderate

Read the supporting source summaries

Source 1: Current prescribing information

dailymed.nlm.nih.gov · Source check Sep 10, 2026

Population: Prescription oral oral immediate-release etodolac capsules or tablets users; short human pharmacology studies where described.

GI bleeding, renal and hematological warnings; assess anemia symptoms rather than assuming nutritional deficiency.

How this applies: Exact current product label. Exact etodolac IN 24605. Racemic immediate-release capsules 200/300 mg and tablets 400/500 mg; extended-release or isolated enantiomer exposures are not assumed equivalent.

Exact oral product label; no measured botanical co-use incidence. Ingredient, route, preparation and comparator differences must be retained.

Source 2: Final regulatory herbal monograph

ema.europa.eu · Source check Sep 10, 2026

Population: Users of defined Salix bark preparations.

Advises against concomitant salicylates or other NSAIDs without medical advice; active ulcer and NSAID hypersensitivity are contraindications.

How this applies: Precaution for medicinal willow products; exact S. alba applicability remains limited by botanical identification.

No exact pair bleeding estimate. Defined medicinal species/preparations cannot authenticate unspecified products. Salix alba is not specifically named among the principal listed species.

Research assessment: · Open full citations ↗

Review and change history

Publication status
Published research summary
Clinical review
Not yet recorded
DateUpdate
Article prepared
Sources checked and article drafted.
Research summary published

Article revision: 6767aad6e0dbc52d

This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.

Full citations require verification. Reading this answer and the source summaries does not.

Taking other supplements or medications?

Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.

Open the interaction checker

Information, not medical advice. Do not change prescribed treatment based on this guide.